Myriad is leveraging our industry-leading protein biomarker products and services offered through our Myriad RBM and Crescendo Bioscience subsidiaries. These subsidiaries are partnering with pharmaceutical companies to improve the performance of clinical studies and develop new companion diagnostic applications, such as:
- Identifying responders versus nonresponders to treatment;
- Expanding indications for approved drugs/drug re-tasking;
- Predicting drug toxicity;
- Therapeutic monitoring; and
Learn more about Myriad RBM.
Learn more about Crescendo Bioscience.